CREB3L1
Basic information
Region (hg38): 11:46277662-46321409
Links
Phenotypes
GenCC
Source:
- osteogenesis imperfecta type 16 (Moderate), mode of inheritance: AR
- osteogenesis imperfecta type 3 (Supportive), mode of inheritance: AD
- osteogenesis imperfecta type 16 (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Osteogenesis imperfecta, type XVI | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Musculoskeletal | 24079343; 30657919 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (2 variants)
- Osteogenesis imperfecta type 16 (2 variants)
- Osteogenesis imperfecta (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CREB3L1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 68 | 73 | ||||
missense | 100 | 111 | ||||
nonsense | 2 | |||||
start loss | 0 | |||||
frameshift | 6 | |||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 1 | |||||
splice region | 4 | 6 | 3 | 13 | ||
non coding | 38 | 19 | 59 | |||
Total | 4 | 2 | 106 | 113 | 28 |
Highest pathogenic variant AF is 0.00000657
Variants in CREB3L1
This is a list of pathogenic ClinVar variants found in the CREB3L1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
11-46277758-C-G | Benign (Oct 09, 2018) | |||
11-46278120-C-A | Likely benign (Aug 11, 2023) | |||
11-46278131-C-A | Uncertain significance (Jan 15, 2022) | |||
11-46278138-G-A | Likely benign (Aug 31, 2022) | |||
11-46278144-C-T | Likely benign (Mar 08, 2023) | |||
11-46278147-G-A | Likely benign (May 29, 2023) | |||
11-46278156-C-T | Likely benign (Aug 19, 2023) | |||
11-46278157-G-T | Uncertain significance (Jun 13, 2017) | |||
11-46278174-C-T | Likely benign (May 22, 2023) | |||
11-46278178-G-C | Uncertain significance (Mar 09, 2022) | |||
11-46278189-C-T | Likely benign (Sep 15, 2021) | |||
11-46278221-G-A | Likely benign (Jul 17, 2023) | |||
11-46296481-C-G | Benign (Jan 19, 2024) | |||
11-46299684-C-G | Benign (Aug 09, 2018) | |||
11-46299917-C-T | Likely benign (Mar 01, 2022) | |||
11-46299936-A-G | Uncertain significance (Jun 12, 2022) | |||
11-46299964-G-A | Osteogenesis imperfecta type 16 | Likely benign (Feb 23, 2023) | ||
11-46299965-G-A | Inborn genetic diseases | Uncertain significance (Apr 07, 2023) | ||
11-46300016-C-T | Inborn genetic diseases | Uncertain significance (Jan 19, 2022) | ||
11-46300043-T-A | Inborn genetic diseases | Uncertain significance (Jan 03, 2024) | ||
11-46300068-C-T | Inborn genetic diseases | Uncertain significance (Jan 29, 2024) | ||
11-46300070-C-T | Inborn genetic diseases | Uncertain significance (Jul 25, 2023) | ||
11-46300084-G-A | Likely benign (Apr 10, 2023) | |||
11-46300093-C-T | Likely benign (Dec 01, 2023) | |||
11-46300104-G-C | Uncertain significance (Jun 22, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CREB3L1 | protein_coding | protein_coding | ENST00000529193 | 12 | 43761 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.985 | 0.0151 | 124639 | 0 | 6 | 124645 | 0.0000241 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.949 | 243 | 288 | 0.843 | 0.0000164 | 3322 |
Missense in Polyphen | 72 | 96.25 | 0.74805 | 1173 | ||
Synonymous | 0.962 | 117 | 131 | 0.893 | 0.00000881 | 1019 |
Loss of Function | 3.90 | 2 | 21.5 | 0.0929 | 0.00000107 | 260 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000942 | 0.0000942 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.0000557 | 0.0000556 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000357 | 0.0000265 |
Middle Eastern | 0.0000557 | 0.0000556 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Transcription factor involved in unfolded protein response (UPR). Binds the DNA consensus sequence 5'-GTGXGCXGC-3' (PubMed:21767813). In the absence of endoplasmic reticulum (ER) stress, inserted into ER membranes, with N-terminal DNA-binding and transcription activation domains oriented toward the cytosolic face of the membrane. In response to ER stress, transported to the Golgi, where it is cleaved in a site-specific manner by resident proteases S1P/MBTPS1 and S2P/MBTPS2. The released N-terminal cytosolic domain is translocated to the nucleus to effect transcription of specific target genes. Plays a critical role in bone formation through the transcription of COL1A1, and possibly COL1A2, and the secretion of bone matrix proteins. Directly binds to the UPR element (UPRE)-like sequence in an osteoblast-specific COL1A1 promoter region and induces its transcription. Does not regulate COL1A1 in other tissues, such as skin (By similarity). Required to protect astrocytes from ER stress-induced cell death. In astrocytes, binds to the cAMP response element (CRE) of the BiP/HSPA5 promoter and participate in its transcriptional activation (By similarity). Required for TGFB1 to activate genes involved in the assembly of collagen extracellular matrix (PubMed:25310401). {ECO:0000250|UniProtKB:Q9Z125, ECO:0000269|PubMed:12054625, ECO:0000269|PubMed:21767813, ECO:0000269|PubMed:25310401}.;
- Disease
- DISEASE: Osteogenesis imperfecta 16 (OI16) [MIM:616229]: An autosomal recessive form of osteogenesis imperfecta, a connective tissue disorder characterized by low bone mass, bone fragility and susceptibility to fractures after minimal trauma. Disease severity ranges from very mild forms without fractures to intrauterine fractures and perinatal lethality. Extraskeletal manifestations, which affect a variable number of patients, are dentinogenesis imperfecta, hearing loss, and blue sclerae. OI16 is a severe form. {ECO:0000269|PubMed:24079343}. Note=The disease may be caused by mutations affecting the gene represented in this entry. OI16 affected patients show a genomic deletion encompassing CREB3L1 and the first exon of DGKZ. The absence of this exon does not affect all DGKZ isoforms, some are still produced at normal level. It cannot be ruled out that DGKZ could contribute to the phenotype, but in view of its role in bone formation, CREB3L1 is a strong OI16-causing candidate (PubMed:24079343). This hypothesis is corroborated by the observation of CREB3L1 knockout mice which exhibit features reminiscent of severe human osteogenesis imperfecta. {ECO:0000269|PubMed:24079343}.;
- Pathway
- PI3K-Akt signaling pathway - Homo sapiens (human);Cortisol synthesis and secretion - Homo sapiens (human);Relaxin signaling pathway - Homo sapiens (human);Aldosterone synthesis and secretion - Homo sapiens (human);Dopaminergic synapse - Homo sapiens (human);Insulin resistance - Homo sapiens (human);Cushing,s syndrome - Homo sapiens (human);Thyroid hormone synthesis - Homo sapiens (human);Vasopressin-regulated water reabsorption - Homo sapiens (human);Huntington,s disease - Homo sapiens (human);TNF signaling pathway - Homo sapiens (human);AMPK signaling pathway - Homo sapiens (human);Thermogenesis - Homo sapiens (human);Glucagon signaling pathway - Homo sapiens (human);Adrenergic signaling in cardiomyocytes - Homo sapiens (human);Prostate cancer - Homo sapiens (human);Longevity regulating pathway - Homo sapiens (human);cAMP signaling pathway - Homo sapiens (human);Estrogen signaling pathway - Homo sapiens (human);Amphetamine addiction - Homo sapiens (human);Viral carcinogenesis - Homo sapiens (human);Hepatitis B - Homo sapiens (human);cGMP-PKG signaling pathway - Homo sapiens (human);Cholinergic synapse - Homo sapiens (human);Alcoholism - Homo sapiens (human);Cocaine addiction - Homo sapiens (human);Insulin secretion - Homo sapiens (human);Melanogenesis - Homo sapiens (human);Human papillomavirus infection - Homo sapiens (human);Focal Adhesion-PI3K-Akt-mTOR-signaling pathway;miRNA regulation of prostate cancer signaling pathways;PI3K-Akt Signaling Pathway;G1 to S cell cycle control;Unfolded Protein Response (UPR);Metabolism of proteins;CREB3 factors activate genes
(Consensus)
Recessive Scores
- pRec
- 0.138
Intolerance Scores
- loftool
- rvis_EVS
- 0.29
- rvis_percentile_EVS
- 71.5
Haploinsufficiency Scores
- pHI
- 0.563
- hipred
- Y
- hipred_score
- 0.594
- ghis
- 0.392
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.721
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Creb3l1
- Phenotype
- growth/size/body region phenotype; homeostasis/metabolism phenotype; cellular phenotype; skeleton phenotype; hematopoietic system phenotype;
Gene ontology
- Biological process
- negative regulation of transcription by RNA polymerase II;osteoblast differentiation;multicellular organism development;negative regulation of gene expression;endoplasmic reticulum unfolded protein response;positive regulation of collagen biosynthetic process;negative regulation of fibroblast growth factor receptor signaling pathway;negative regulation of transcription, DNA-templated;extracellular matrix constituent secretion;negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway;negative regulation of sprouting angiogenesis;positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress
- Cellular component
- nuclear chromatin;nucleus;endoplasmic reticulum;endoplasmic reticulum membrane;membrane;integral component of membrane
- Molecular function
- DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription repressor activity, RNA polymerase II-specific;DNA-binding transcription activator activity, RNA polymerase II-specific;chromatin binding;protein binding;cAMP response element binding;transcription regulatory region DNA binding;SMAD binding